ProQR Therapeutics NV (NAS:PRQR)
$ 1.88 -0.01 (-0.53%) Market Cap: 153.53 Mil Enterprise Value: 63.26 Mil PE Ratio: 0 PB Ratio: 4.06 GF Score: 39/100

ProQR Therapeutics NV at Chardan Genetic Medicines Conference (Virtual) Transcript

Oct 05, 2021 / 08:00PM GMT
Release Date Price: $7.64 (-5.33%)
Keay Nakae
Chardan Capital Markets LLC - Analyst

I'd like to introduce our next guest from ProQR Therapeutics, Chief Financial Officer, Smital Shah. The format for this session is a 25-minute fireside chat. (Operator Instructions). With that, Smital, welcome. Thanks for joining us again this year.

Questions & Answers

Keay Nakae
Chardan Capital Markets LLC - Analyst

And to start, can you please provide a couple of minutes of introductory comments about the state of the business for ProQR, summarizing your differentiated approach, and what's been achieved in 2021 year to date?

Smital Shah
ProQR Therapeutics N.V. - Chief Business and Financial Officer

Yes, absolutely. First of all, thank you, Keay, for having us and thank you to Chardan for inviting us again to a very productive conference. I really appreciate that. I also, before I start, want to point people to our website and our forward-looking statements. Also, do take a look when you get the chance.

I think to your question on the state of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot